FRANKLIN LAKES, N.J.--(BUSINESS WIRE)--Nov. 16, 2005--ReGen Biologics, Inc. (OTC:RGBI) an orthopedic products company that develops, manufactures, and markets innovative tissue growth and repair products, announced today an exclusive two-year distribution agreement with Hoscenter to market the ReGen(R) CMI(TM) in most areas of Spain. The CMI is a type I collagen implant designed to facilitate growth of new tissue to replace removed or missing meniscus tissue in the human knee. Hoscenter will also market ReGen’s SharpShooter(R) Tissue Repair System on a non-exclusive basis. “Hoscenter will be an excellent partner for us in Spain, where they cover all but the Catalan area,” said Gerald E. Bisbee, Jr., Ph.D., Chairman and Chief Executive Officer of ReGen Biologics. “This agreement furthers the availability of the CMI and SharpShooter in another key European market.” ReGen previously announced the establishment of a wholly owned subsidiary in Switzerland as well as a distribution partner for Italy. Speaking on behalf of Hoscenter, Enrique Garcia Fernandez, General Manager of Hoscenter remarked, “We are pleased to be working directly with ReGen Biologics in representing the CMI and SharpShooter products. There are approximately 1500 orthopedic surgeons in Spain, and they have significant interest in products such as these offering innovative approaches to orthopedic conditions.”
